A direct reading of the Melanotan 2 photoprotection literature — melanocortin agonism, eumelanin synthesis, and the afamelanotide-in-EPP evidence, summarized straight from the studies.
Melanotan Direct

The Literature

Melanotan 2 References

Every source cited across this digest, numbered and linked to its PubMed record.

About these sources

Every quantitative claim and study description on this site maps to a numbered entry below. Sources are peer-reviewed journal articles, controlled clinical studies, case reports, and reviews indexed in PubMed. Each entry links to its PubMed record, where the full abstract and the publisher's version can be reached. Where a study concerns the related analog afamelanotide (Melanotan 1) rather than Melanotan 2 itself, the title makes that clear — those entries are included precisely because the photoprotection rationale draws on them, and the distinction matters.

  1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. ↗
  2. Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sci. 1996;58(20):1777-1784. ↗
  3. Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. ↗
  4. Dorr RT, Dvorakova K, Brooks C, Lines R, Levine N, Schram K, Miketova P, Hruby V, Alberts DS. Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans. Photochem Photobiol. 2000;72(4):526-532. ↗
  5. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015;373(1):48-59. ↗
  6. Mazzarino M, et al. Barbie drug identification: Not a child's play. J Forensic Sci. 2024;69(6). ↗
  7. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. 2021. ↗
  8. The 'Barbie Drug' — marketing and perceptions of melanotan on social media. 2025. ↗
  9. Eruptive dysplastic nevi following melanotan use. 2012. ↗
  10. alpha-Melanocyte-stimulating hormone-induced eruptive nevi. 2009. ↗
  11. Eruptive melanocytic naevi following melanotan injection. 2009. ↗
  12. Eruptive naevi and darkening of pre-existing naevi 24 h after a single mono-dose injection of melanotan II. 2014. ↗
  13. Dermoscopic changes in melanocytic nevi during use of melanotan II. Hautarzt. 2012;63(11):880-884. ↗
  14. Melanoma associated with the use of melanotan-II. 2014. ↗
  15. Changes of melanocytic lesions induced by Melanotan injections and sun bed use in a teenage patient with FAMMM syndrome. 2012. ↗
  16. Melanotan-associated melanoma. 2011. ↗
  17. Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. 2012. ↗
  18. Peters B, Hadimeri H, Wahlberg R, Afghahi H. Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN Case Rep. 2020;9(2):159-161. ↗
  19. Melanotan II overdose associated with priapism. 2013. ↗
  20. Melanotan Tanning Injection: A Rare Cause of Priapism. 2021. ↗
  21. Habbema L, et al. Melanotan-induced priapism: a hard-earned tan. BMJ Case Rep. 2019;12(2):e227644. ↗
  22. Melanotan and the posterior reversible encephalopathy syndrome. 2013. ↗
  23. Hemodynamic actions and mechanisms of systemically administered alpha-MSH analogs in mice. 2012. ↗
  24. Systemic but not central nervous system nitric oxide synthase inhibition exacerbates the hypertensive effects of chronic melanocortin-3/4 receptor activation. 2011. ↗
  25. Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. 2003. ↗
  26. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. 2015. ↗
  27. LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs. 2021. ↗
  28. Operation resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe. 2016. ↗
  29. Langan EA, Nie Z, Rhodes LE. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? Br J Dermatol. 2010;163(3):451-455. ↗
  30. The unregulated use of melanotan-II is of public health interest to Australian dermatologists. 2017. ↗
  31. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. 2017. ↗
  32. Falsification of biotechnology drugs: current dangers and/or future disasters? 2018. ↗
  33. Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X, Minder EI. Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. 2015;172(6):1601-1612. ↗
  34. Preformulation studies with melanotan-II: a potential skin cancer chemopreventive peptide. 1994. ↗
  35. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. 2003. ↗
  36. Change in moles linked to use of unlicensed "sun tan jab". 2009. ↗
  37. Eliason NL, Martin L, Low MJ, Sharpe AL. Melanocortin receptor agonist melanotan-II microinjected in the nucleus accumbens decreases appetitive and consumptive responding for food. Neuropeptides. 2022;96:102289. ↗
  38. Bonchev A. Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. Life (Basel). 2026;16(2):265. ↗
  39. Rossler AS, Pfaus JG, Kia HK, Bernabe J, Alexandre L, Giuliano F. The melanocortin agonist, melanotan II, enhances proceptive sexual behaviors in the female rat. Pharmacol Biochem Behav. 2006;85(3):514-521. ↗